Moore Capital Management’s GSK GSK Stock Holding History

Moore Capital Management’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-80,000	Closed	-$4.17M	–	338
2015 Q2	$4.17M	Buy	+80,000	New	+$4.5M	0.09%	225
2015 Q1	–	Sell	-400,000	Closed	-$21.4M	–	437
2014 Q4	$21.4M	Buy	400,000 +160,000	+67%	+$8.95M	0.67%	34
2014 Q3	$13.8M	Buy	+240,000	New	+$14.7M	0.32%	79

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Moore Capital Management's GSK Position: Q4 2023 in Review

Moore Capital Management sold out of GSK (GSK) in Q4 2023, closing a stake of 87,087 shares — an estimated $3.16M sold.

Moore Capital Management first reported a position in GSK in Q1 2014 and held it in 3 quarters. The position peaked at $4.01M in Q1 2014. 895 funds tracked by Wall St. Rank hold GSK as of Q4 2023.

Moore Capital Management reported no remaining GSK position as of Q4 2023 after selling out during the quarter.
Moore Capital Management sold 87,087 GSK shares in Q4 2023, an estimated $3.16M.
Moore Capital Management first reported a position in GSK in Q1 2014 and held it in 3 quarters.
Moore Capital Management's GSK position peaked at $4.01M in Q1 2014.
895 funds tracked by Wall St. Rank held GSK as of Q4 2023.

Based on Moore Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.